OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL

October 12th 2020

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Dr. McDermott on the Next Steps of the DASL-HiCAP Trial in High-Risk Prostate Cancer

October 12th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the next steps of the phase 3 DASL-HiCAP trial in high-risk prostate cancer.

Dr. O’Regan on the Risk of Cardiomyopathy With Trastuzumab in HER2+ Breast Cancer

October 12th 2020

Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.

Dr. Tseng on the Significance of the TARPSWG Analysis in Retroperitoneal Sarcoma

October 9th 2020

William W. Tseng, MD, discusses the significance of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Dr. Gradishar on the Treatment Landscape in Metastatic HER2+ Breast Cancer

October 9th 2020

William J. Gradishar, MD, discusses the current treatment landscape in metastatic HER2-positive breast cancer.

Dr. Vesole on Developing Off-the-Shelf CAR T-Cell Therapy in Multiple Myeloma

October 9th 2020

David H. Vesole, MD, PhD, discusses the importance of developing off-the-shelf CAR T-cell therapy products in multiple myeloma.

Dr. Davids on Factors to Inform Treatment Selection in CLL

October 9th 2020

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.

Dr. Nazha on the Risk of Progression to Myelofibrosis in Polycythemia Vera

October 9th 2020

Aziz Nazha, MD, discusses the risk of progression to myelofibrosis in patients with polycythemia vera.

Dr. D’Amato on the Diminishing Role of Chemotherapy in Sarcoma

October 9th 2020

Gina Z. D'Amato, MD, discusses the diminishing role of chemotherapy in sarcoma.

Dr. Hill on Managing CRS in Patients Treated With CAR T-Cell Therapy

October 9th 2020

Brian T. Hill, MD, PhD, discusses the management of cytokine release syndrome in patients with hematologic malignancies who are treated with CAR T-cell therapy.

Dr. Deol on the Curative Potential of CAR T-Cell Therapy in ALL

October 8th 2020

Abhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.

Dr. Pemmaraju on the Potential Role of Novel Therapies in MPNs

October 8th 2020

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

Dr. Yap on the Rationale for the SEASTAR Trial in Advanced Solid Tumors

October 8th 2020

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.

Dr. Pleyer on Next Steps With Ibrutinib Plus Short-Course Fludarabine in Previously Untreated CLL

October 8th 2020

Christopher Pleyer, MD, discusses the next steps with the combination of ibrutinib and short-course fludarabine in previously untreated chronic lymphocytic leukemia.

Dr. Maki on the Evolving Treatment Landscape in Soft Tissue Sarcoma

October 8th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the evolving treatment landscape of soft tissue sarcoma.

Dr. Kantoff on the Need to Develop New Therapies in mCRPC

October 8th 2020

Philip W. Kantoff, MD, discusses the need to develop new therapies in metastatic castration-resistant prostate cancer.

Dr. Pleyer on Remaining Questions With Ibrutinib Plus Short-Course Fludarabine in CLL

October 8th 2020

Christopher Pleyer, MD, discusses the safety and effectiveness of ibrutinib plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Dr. Lin on Treatment Challenges in HER2+ Breast Cancer and Brain Metastases

October 8th 2020

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

Dr. Burris on the Exploration of PARP Inhibitors in TNBC

October 8th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

Dr. Concin on the Rationale for the LIO-1 Trial in Advanced Gynecologic Malignancies

October 7th 2020

Nicole Concin, MD, discusses the rationale for the phase 1/2 LIO-1 trial in advanced gynecologic malignancies.